Scholarlink

Background <p>Intralesional curettage of benign bone lesions often leaves contained voids requiring augmentation. GeneX&#xa0;(Biocomposites Ltd., Keele, UK)&#xa0;is an injectable synthetic bone graft substitute, comprised of beta-tricalcium phosphate and calcium sulfate,&#xa0;which may simplify postoperative surveillance due to its osteoconductivity and resorption. Evidence for GeneX use in this setting is limited and based mainly on small, heterogeneous series; we report further real-world experience from a tertiary musculoskeletal oncology centre.</p> Methods <p>We retrospectively reviewed 21 consecutive patients (mean age, 36 years)&#xa0;who underwent curettage of benign bone tumours and grafting with GeneX between April 2019 and May 2025. The most common tissue diagnoses were enchondroma and aneurysmal bone cysts, and mean preoperative tumour diameter was 31 mm.&#xa0;Primary outcome measures were radiographic incorporation or resorption, complications, restoration of function, and recurrence.</p> Results <p>Graft resorption was demonstrated in 19 cases (90%) within 3–12 months. In the remaining two patients, resorption could not be confirmed due to limited follow-up imaging and infection requiring graft removal with revision of metalwork, respectively. All patients returned to full weight bearing, most by 6 weeks, and no tumour recurrences were observed during a mean follow-up of&#xa0;35 months.</p> Conclusions <p>In this single-centre cohort, GeneX appeared to be a safe and practical option for filling contained defects following curettage of benign bone tumours, with encouraging radiographic remodelling, timely functional recovery, and no recurrences. These findings supplement the existing literature on synthetic bone graft substitutes in orthopaedic oncology, but require confirmation in controlled comparative studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Injectable synthetic bone graft substitute (GeneX) in the surgical management of benign bone tumours: further experience from a tertiary musculoskeletal oncology centre

  • 期刊论文

  • 发表日期：

    2026年2月10日

查看全文
  • Joseph J McAuley,
  • Nima Razii,
  • Jack O Clark,
  • Ashish Mahendra,
  • Sanjay Gupta

摘要

Background

Intralesional curettage of benign bone lesions often leaves contained voids requiring augmentation. GeneX (Biocomposites Ltd., Keele, UK) is an injectable synthetic bone graft substitute, comprised of beta-tricalcium phosphate and calcium sulfate, which may simplify postoperative surveillance due to its osteoconductivity and resorption. Evidence for GeneX use in this setting is limited and based mainly on small, heterogeneous series; we report further real-world experience from a tertiary musculoskeletal oncology centre.

Methods

We retrospectively reviewed 21 consecutive patients (mean age, 36 years) who underwent curettage of benign bone tumours and grafting with GeneX between April 2019 and May 2025. The most common tissue diagnoses were enchondroma and aneurysmal bone cysts, and mean preoperative tumour diameter was 31 mm. Primary outcome measures were radiographic incorporation or resorption, complications, restoration of function, and recurrence.

Results

Graft resorption was demonstrated in 19 cases (90%) within 3–12 months. In the remaining two patients, resorption could not be confirmed due to limited follow-up imaging and infection requiring graft removal with revision of metalwork, respectively. All patients returned to full weight bearing, most by 6 weeks, and no tumour recurrences were observed during a mean follow-up of 35 months.

Conclusions

In this single-centre cohort, GeneX appeared to be a safe and practical option for filling contained defects following curettage of benign bone tumours, with encouraging radiographic remodelling, timely functional recovery, and no recurrences. These findings supplement the existing literature on synthetic bone graft substitutes in orthopaedic oncology, but require confirmation in controlled comparative studies.